Active Biotech AB (publ) (STO:ACTI)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.0438
-0.0013 (-2.88%)
At close: Mar 6, 2026
-49.19%
Market Cap 115.46M
Revenue (ttm) n/a
Net Income (ttm) -38.50M
Shares Out 2.64B
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 16,272,710
Average Volume 23,019,192
Open 0.0460
Previous Close 0.0451
Day's Range 0.0434 - 0.0464
52-Week Range 0.0370 - 0.3400
Beta 1.50
RSI 47.07
Earnings Date Feb 12, 2026

About Active Biotech AB

Active Biotech AB (publ), a biotechnology company, engages in the research, development, and production of pharmaceutical products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase Ib/IIa clinical trial to treat relapsed refractory multiple myeloma; Laquinimod, a mechanism which is in phase 1 for the treatment of severe inflammatory eye diseases, such as non-infectious uveitis; Tasquinimod, an orally active small molecule immunomodulator that blocks tumor-promoting signals in the bone marrow microenvir... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1983
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol ACTI
Full Company Profile

Financial Performance

Financial Statements

News

Active Biotech AB: Active Biotech's patent related to a pharmaceutical formulation of tasquinimod will be granted in the US

Lund, November 25, 2025, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the US Patent and Trademark Office (USPTO) has issued a notification that the company's patent application rela...

3 months ago - Finanz Nachrichten